iBio Inc., a clinical‑stage biotechnology company, released its fiscal‑year‑ending June 30, 2026 financials on Friday, reporting a wider net loss than the prior year. The company attributed the increase to higher expenses tied to its expanding clinical research program, while revenue remained modest and unchanged from the previous period.
The report highlighted that Phase 1 testing of IBIO‑600, iBio’s investigational therapy for obesity, is progressing on schedule. The trial has successfully enrolled its target cohort and early safety data have been deemed acceptable, allowing the study to move into its dose‑escalation phase ahead of the planned Q4 data readout.
Management reaffirmed its commitment to advancing the obesity pipeline despite the loss, noting that additional capital will be raised through a forthcoming equity offering. The company also announced an investor webcast for early September to discuss the Phase 1 results and outline its financing roadmap.
